UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 98,725 Shares of Moderna, Inc. $MRNA

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC reduced its position in Moderna, Inc. (NASDAQ:MRNA) by 6.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,521,849 shares of the company’s stock after selling 98,725 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.38% of Moderna worth $106,575,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in MRNA. Allied Private Wealth LLC bought a new stake in Moderna in the 2nd quarter worth approximately $30,000. Archer Investment Corp bought a new position in shares of Moderna during the 2nd quarter valued at approximately $36,000. Canton Hathaway LLC bought a new position in shares of Moderna during the 1st quarter valued at approximately $31,000. Frazier Financial Advisors LLC purchased a new position in shares of Moderna in the second quarter valued at $45,000. Finally, Freestone Grove Partners LP purchased a new position in shares of Moderna in the second quarter valued at $46,000. 75.33% of the stock is owned by institutional investors.

Insider Transactions at Moderna

In related news, President Stephen Hoge sold 53,336 shares of Moderna stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $51.37, for a total transaction of $2,739,870.32. Following the completion of the transaction, the president directly owned 1,483,848 shares of the company’s stock, valued at approximately $76,225,271.76. The trade was a 3.47% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Thyme Klinger sold 3,471 shares of the company’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $50.00, for a total transaction of $173,550.00. Following the transaction, the insider owned 67,468 shares in the company, valued at $3,373,400. The trade was a 4.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 10.80% of the stock is currently owned by insiders.

Moderna Stock Performance

NASDAQ:MRNA opened at $154.27 on Wednesday. The firm has a market capitalization of $61.59 billion, a PE ratio of -19.31 and a beta of 1.09. The stock’s fifty day moving average is $80.59 and its 200 day moving average is $61.34. Moderna, Inc. has a fifty-two week low of $22.28 and a fifty-two week high of $176.66. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.18 and a current ratio of 2.29.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Friday, July 31st. The company reported ($1.97) EPS for the quarter, topping the consensus estimate of ($2.03) by $0.06. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The company had revenue of $145.00 million during the quarter, compared to analyst estimates of $102.93 million. During the same period in the previous year, the firm earned ($2.13) earnings per share. Moderna’s quarterly revenue was up 2.1% compared to the same quarter last year. On average, sell-side analysts anticipate that Moderna, Inc. will post -6.11 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on MRNA. Argus raised shares of Moderna from a “hold” rating to a “buy” rating and set a $180.00 price target on the stock in a research note on Friday, August 28th. JPMorgan Chase & Co. boosted their target price on shares of Moderna from $40.00 to $77.00 and gave the stock an “underweight” rating in a report on Friday, August 21st. Bank of America upgraded shares of Moderna from an “underperform” rating to a “neutral” rating in a research report on Wednesday, August 19th. Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $130.00 price target on shares of Moderna in a report on Wednesday, August 19th. Finally, UBS Group lifted their price target on Moderna from $50.00 to $150.00 and gave the stock a “neutral” rating in a research report on Thursday, August 20th. Seven investment analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, Moderna presently has an average rating of “Hold” and an average target price of $80.53.

Trending Headlines about Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Positive late-stage results from Moderna and Merck’s personalized melanoma vaccine remain the primary catalyst. The data reinforced expectations that Moderna can expand beyond COVID-19 vaccines into cancer immunotherapy and potentially create a significant long-term revenue stream. Moderna Stock More Than Doubled in August. Is the Stock a Buy, a Hold, or a Sell?
• Positive Sentiment: Options activity was notably bullish, with investors purchasing 106,605 call contracts—about 35% above typical volume. The activity suggests increased speculative interest in further gains, although options positioning can also amplify volatility.
• Positive Sentiment: Moderna’s updated COVID-19 vaccine approvals and the company’s recent momentum have helped restore investor confidence in its commercial and regulatory execution. Shares more than doubled during August, making the stock one of the market’s strongest performers. Moderna (MRNA) Soars 156% in August — Here’s What Propelled The Rally
• Neutral Sentiment: Moderna will present at the Morgan Stanley Global Healthcare Conference on September 14 and the Bernstein Healthcare Forum on September 23. These events could provide updates on the oncology pipeline, vaccine demand and the path to profitability, but no new financial information was announced. Moderna to Present at Upcoming Conferences in September 2026
• Negative Sentiment: GSK advanced its competing mRNA influenza vaccine into a Phase III trial, increasing future competitive pressure shortly after Moderna received approval for the first seasonal flu mRNA vaccine. Investors appear to be treating the threat as manageable for now, with greater emphasis on Moderna’s cancer program. GSK hopes to take on Moderna as it moves mRNA flu vaccine to Phase III trial
• Negative Sentiment: Brookline Capital Markets modestly reduced its FY2029 and FY2030 EPS estimates, while maintaining a Buy rating. The cuts signal limited near-term financial visibility as Moderna remains loss-making and analysts expect a full-year loss.

Moderna Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.